Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

16 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

     

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

  • (a) Validation of the global proteome and acetylome results. AS and BE2 cells were treated with 10 μM of perifosine for 16 h. Total proteins were extracted and 30 μg of protein was analyzed for integrin β5 and acetyl-Histone H2B (Lys12) by western blotting. GAPDH was used as loading control.

    Sci Rep, 2017, 7:41950. Perifosine (KRX-0401) purchased from Selleck.

    Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

    Established cell lines (A549 and H460 lines) were un-stimulated (“C”, same for all figures), or treated with indicated concentration of perifosine (0.3-10 μM) or plus ABT-737 (100 nM), cells were then cultured for indicated time, and cell growth was tested by MTT assay (a, b, d, e) or by colony formation assay (c and f). “Prf” stands for perifosine (Same for all figures). The results presented were representative of three independent experiments. The values were expressed as the means ± SD. *p < 0.05 vs “C” group. #p < 0.05 compared with the perifosine only group without ABT-737 co-treatment.

    Biochem Biophys Res Commun, 2016, 473(4):1170-6. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  Mn\0SpVv[3Srb36gRZN{[Xl? MV2wMlUwOS9{LkWg{txO NFnGOVI{KGh? MVfy[YR2[2W|IITo[UBj[XOjbDDDRkB1gXKxc3nu[UBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NY\iW2pKOjZyOUe4O|M>
T24 BC  NF3zPWlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYewMlUwOS9{LkWg{txO M{jqc|I1KGh? MYTlcohidmOnczDzc5Ji\mWwaXKtbY5lfWOnZDDj[YxtKH[rYXLpcIl1gSCmZXPy[YF{\Q>? MXyyOlA6Pzh5Mx?=
T24 BC  MkPBRZBweHSxc3nzJGF{e3OjeR?= M1;1d|IvPSEQvF2= Mmn1NlQhcA>? NW\POplse2Wwc3n0bZpmeyCEQzDj[YxteyC2bzDzc5Ji\mWwaXKtbY5lfWOnZDDhdI9xfG:2aXRCpC=> MVKyOlA6Pzh5Mx?=
HepG2 MnTKSpVv[3Srb36gRZN{[Xl? MoLvNlDDqM7:TR?= M1j5SVI1yqCq M2j1VpBzd2S3Y3XzJIFvKGmwdHXud4Uh[3m2b4DsZZNucWNidnHjeY9tcXqjdHnvckBkd3K{ZYPwc45lcW6pIITvJIEhdm:2YXLs[UBlcWyjdHH0bY9vKG:oIITo[UBGWiClaYP0[ZJvew>? MUeyOVk{PDJ|Mh?=
U-87 MG  MnvxSpVv[3Srb36gRZN{[Xl? Ml7zNlDDqM7:TR?= M1W0XlI1yqCq MlnQbY5kemWjc3XzJIRwfWKuZT3t[Y1jemGwZTDic5Vv\CC|dIL1Z5R2emW| NVX1XVhuOjV7M{SyN|I>
HepG2 NHfPc5RHfW6ldHnvckBCe3OjeR?= NVvuVplXOjEEoN88US=> MkHkOk8zPCCq MYTpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCOQ{OtTWkh[2:2cnXheIVlKHerdHigR3E> M4C4SFI2QTN2MkOy
U-87 MG  MYXGeY5kfGmxbjDBd5NigQ>? Mo\FNlDDqM7:TR?= NIP6fFc3NzJ2IHi= NHn2NnRqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDMR|MuUUliY3;0doVifGWmIIfpeIghS1F? MnSyNlU6OzR{M{K=
HepG2 NHfNNmlHfW6ldHnvckBCe3OjeR?= NULmSo1bOjEEoN88US=> NXHxbHVnPi9{NDDo MlG1[IVkemWjc3XzJGxEOy2LSTDk[Ydz[WSjdHnvcuKh\nKxbTC2JIg> M1LaflI2QTN2MkOy
U-87 MG  MnzhSpVv[3Srb36gRZN{[Xl? NUnqUXhHOjEEoN88US=> NXnofVJbPi9{NDDo MnnKbY5kemWjc3XzJJRp\SCjdYTvdIhi\2mlIH\seZghKGG2IE[gbEB4cGmuZTDpcohq[mm2czD0bIl{KG[udYigZZQhOjSq MWCyOVk{PDJ|Mh?=
HepG2 NHG3ZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWyNE81OCEQvF2= MlTwNlQwPDhiaB?= MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2XyTlI2QTN2MkOy
U-87 MG  MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmyNE81OCEQvF2= MXGyOE81QCCq M1nZTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MnewNlU6OzR{M{K=
A549 MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\LZ|AvOy1zMDFOwG0> NUTGUFlQOjRxN{KgbC=> M{LLb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NV\4XW4xOjV4OUe4PVk>
H460 MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LvS|AvOy1zMDFOwG0> M1HUOVI1Nzd{IHi= MnL4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mk\iNlU3QTd6OUm=
A549 NV3M[5JrSXCxcITvd4l{KEG|c4PhfS=> NUDxNIpLOS9|IN88US=> Mo[2OFghcA>? MoeybY5lfWOnczDhdI9xfG:|aYO= MkHxNlU3QTd6OUm=
H460 Mn\SRZBweHSxc3nzJGF{e3OjeR?= M2nXSlEwOyEQvF2= NXjQdmhlPDhiaB?= MlfUbY5lfWOnczDhdI9xfG:|aYO= NEixR|EzPTZ7N{i5PS=>
A549 NFjHcGJHfW6ldHnvckBCe3OjeR?= MVOzJO69VQ>? NXrqN5lEQCCq Mn3OZoxw[2u|IFHLWEBi[3SrdnH0bY9v NFXU[oIzPTZ7N{i5PS=>
H460 NXv3d5duTnWwY4Tpc44hSXO|YYm= M3:wdlMh|ryP Ml7JPEBp MVTicI9kc3NiQVvUJIFkfGm4YYTpc44> NY\DemVxOjV4OUe4PVk>
A549 M2XrWGZ2dmO2aX;uJGF{e2G7 MmHKN{DPxE1? NWnUOlliQCCq NWfsXIFG[myxY3vzJI1VV1KFMTygZY5lKEWUSz3NRXBMKGGldHn2ZZRqd25iY3;tZolv\WRid3n0bEBOTUtvMU[y NXX3cnhHOjV4OUe4PVk>
H460 NULuSWo3TnWwY4Tpc44hSXO|YYm= M{e1UlMh|ryP M3XGZlghcA>? MUHicI9kc3NibWTPVmMyNCCjbnSgSXJMNU2DUFugZYN1cX[jdHnvckBkd22kaX7l[EB4cXSqIF3FT{0yPjJ? Mom4NlU3QTd6OUm=
RMG1 NF7CXGlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVGxMVMxKM7:TR?= M{PTUlczKGh? M3PkbIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVfhbJFDOjV3MUmxOFg>
RMG2 NIL5R5RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYX3c3JQOS1|MDFOwG0> MlfBO|IhcA>? Moiw[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M3TzSVI2PTF7MUS4
KOC7C M1jXWmNmdGxiVnnhZoltcXS7IFHzd4F6 NVfSdYhsOS1|MDFOwG0> MmPnO|IhcA>? NHy2eoJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NGHLfmIzPTVzOUG0PC=>
HAC2 NGPnUmpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3;M[lEuOzBizszN M1ftNVczKGh? M3jROIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M4fmblI2PTF7MUS4
RMG2 NIn4O4tE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGTmS3EyNTNyIN88US=> NWPsbWM4PDhiaB?= MYjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M3HRclI2PTF7MUS4
OVISE NFSzeVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHLnU3cyNTNyIN88US=> NVvTSoVvPDhiaB?= MYPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M336XFI2PTF7MUS4
SKOV3 NXPNdVlKS2WubDDWbYFjcWyrdImgRZN{[Xl? M4DJSFEuOzBizszN MmHjOFghcA>? NETZSXFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NV61SYp3OjV3MUmxOFg>
A2780 NX\Bcm1RS2WubDDWbYFjcWyrdImgRZN{[Xl? M1S0TlEuOzBizszN MV:0PEBp NWXtWVA5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NX3RNGpoOjV3MUmxOFg>
RMG1 M4rjTWFxd3C2b4Ppd{BCe3O|YYm= Mlf4N|Ah|ryP MVSyOEBp MoLSbY5lfWOnczDhdI9xfG:|aYO= MWmyOVUyQTF2OB?=
RMG2 MmTURZBweHSxc3nzJGF{e3OjeR?= NV\WZZNmOzBizszN M2rlW|I1KGh? MlKzbY5lfWOnczDhdI9xfG:|aYO= M3PmWFI2PTF7MUS4
HCC1806 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i2d|AuOTBizszN MYi0PEBp MVnFR|UxRTJwOEVihKnDueLCiUCuNFch|ryP MVqyOVI6OzV5Nh?=
MDA-MB-231  NIXGZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPkNE0yOCEQvF2= M{PMOlQ5KGh? MV3FR|UxRTFwMURihKnDueLCiUCuNFch|ryP NH2xeWczPTJ7M{W3Oi=>
GL-1 NFjnXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TVRlAvOeLCk{GwNQKBkc7:TR?= NFXPUJk1QCCq NIjHeoFKSzVyPUmuPVEh|ryP NI\4THkzPDh6MUWwPC=>
CLBL-1 M1W2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWwMlHjiJNzMEFihKnPxE1? MoDIOFghcA>? M2KzfWlEPTB;M{OuNEDPxE1? MlzRNlQ5QDF3MEi=
UL-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn5NE4y6oDVMUCw5qCK|ryP MWW0PEBp MV3JR|UxRTdwMEGg{txO MYiyOFg5OTVyOB?=
Ema MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[wMlHjiJNzMEFihKnPxE1? MoPGOFghcA>? M37PSmlEPTB;NUiuO{DPxE1? NUjlSlBYOjR6OEG1NFg>
PANC-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jST|AuOjVizszN NGXaeG44OiCq NH7OO49qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NGK4cGozPDVzOUe1NS=>
MIA M1n3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:wMVI2KM7:TR?= M1LuUFczKGh? MmXrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MUWyOFUyQTd3MR?=
AsPC-1 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCwMVI2KM7:TR?= NYjITHRiPzJiaB?= MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NEmwToMzPDVzOUe1NS=>
PANC-1 MnPhSpVv[3Srb36gRZN{[Xl? NYnuc3FuOC53IN88US=> MXyyOEBp MlnXbY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh NG\ybHgzPDVzOUe1NS=>
MIA M2XiXmZ2dmO2aX;uJGF{e2G7 M3\GUFAvPSEQvF2= MXOyOEBp MXPpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> NFK1Z48zPDVzOUe1NS=>
AsPC-1 MX;GeY5kfGmxbjDBd5NigQ>? M4GzO|AvPSEQvF2= NILIdowzPCCq NIfSOnhqdmirYnn0d{BCc3RuIGO2T|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB? NVrWWZB6OjR3MUm3OVE>
U87MG M3;RfWNmdGxiVnnhZoltcXS7IFHzd4F6 M4G1U|AuOjVizszN NXvab2FDOjRvOU[gbC=> MX7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MV2yOFA3PTV{Mh?=
SGC7901  MkPPSpVv[3Srb36gRZN{[Xl? MWKwMlc2NzFywrFOwG0> MWC0PEBp M2r5cYRm[3KnYYPld{BxNUGtdDCoV4VzKDR5MzmsJJAuT1ONM98yJEhU\XJiOTmsJIFv\CCFLV3ZR{Bt\X[nbIRCpC=> M3nyRlI{QTF{MkS2
MGC803  NGPYeotHfW6ldHnvckBCe3OjeR?= NGrWXGsxNjd3L{GwxsDPxE1? NGPYSVE1QMLiaB?= NWr1NFdl\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh MUSyN|kyOjJ2Nh?=
TykNu NHTCN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNwNTFOwG0> MWGyN|g4PzBzMh?=
TykNuR NUPJVopTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVwNTFOwG0> MWOyN|g4PzBzMh?=
M41 NXHXZo83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvrTZhKSzVyPUK0Mlch|ryP NF7UVXozOzh5N{CxNi=>
M41R NFPLcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H0SmlEPTB;MUmuPEDPxE1? NFrYZnozOzh5N{CxNi=>
OVCAR8 NHTFb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTxTWM2OD1|MT6xJO69VQ>? NI[0PFkzOzh5N{CxNi=>
HeyA8 NX3nfIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPOTWM2OD1{ND6zJO69VQ>? MnvwNlM5PzdyMUK=
A2780CP MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq5[|MxUUN3ME23MlYh|ryP NIWzOo4zOzh5N{CxNi=>
OVCAR5 NUnF[29NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTZwNzFOwG0> MmfsNlM5PzdyMUK=
A2780S NXnnWY9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vFd2lEPTB;MUSuOUDPxE1? NGTmPIIzOzh5N{CxNi=>
MCAS MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzaTWM2OD1zMj61JO69VQ>? NHXpXpUzOzh5N{CxNi=>
NCI-H727 NETPUFdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlTnNE0yODBizszN MUGyOE84OiCq M3\GOYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NEPtT20zOjR7OUSzOy=>
GOT1 MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnG5NE0yODBizszN M2j3d|I1Nzd{IHi= NXjReGFt\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MWiyNlQ6QTR|Nx?=
BON1 NU[0UppPS2WubDDWbYFjcWyrdImgRZN{[Xl? NHq4VGUxNTFyMDFOwG0> NHzaclgzPC95MjDo NHiz[Wpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M1X0WFIzPDl7NEO3
BON1 NWXUXnpRSXCxcITvd4l{KEG|c4PhfS=> MXewMVExKM7:TR?= MlTyNlQhcA>? M{f1Uolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= MmrONlI1QTl2M{e=
BON1 MmHjSpVv[3Srb36gRZN{[Xl? M12zRlcvPS9zMDFOwG0> M3XuUlghcA>? M{TFOoRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kB1cGViYX70bU1ieG:ydH;0bYMheHKxdHXpcpMhSkOOMjDhcoQhSmOuLWjM MlrMNlI1QTl2M{e=
Kasumi-1 Mkm3R4VtdCCYaXHibYxqfHliQYPzZZk> MlnUNE0zOCEQvF2= NILVcJYzPC92ODDo MmjM[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M3[3bFIzPDB5MkK4
HL-60 MkXtR4VtdCCYaXHibYxqfHliQYPzZZk> MY[wMVIxKM7:TR?= NWTSVZp6OjRxNEigbC=> NVf3dGE1\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MVWyNlQxPzJ{OB?=
Kasumi-1 MoDSRZBweHSxc3nzJGF{e3OjeR?= NX3ZNZBbOTBizszN NF\MeWYzPCCq MVTpcoR2[2W|IHHwc5B1d3Orcx?= NF;i[GQzOjRyN{KyPC=>
HL-60 MX\BdI9xfG:|aYOgRZN{e2G7 MUixNEDPxE1? NVXhdoVKOjRiaB?= MoXWbY5lfWOnczDhdI9xfG:|aYO= MX[yNlQxPzJ{OB?=
Kasumi-1 NUXHU5g4TnWwY4Tpc44hSXO|YYm= M2\TZlIvPS93L{GwJO69VQ>? NH7kPXkzPCCq NWP3W4xb\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy|wrDkc5NmNWSncHXu[IVvfGy7 NGPrR2UzOjRyN{KyPC=>
HL-60 M17LPWZ2dmO2aX;uJGF{e2G7 NFrSNnYzNjVxNT:xNEDPxE1? NEXXW28zPCCq NV3iUIxV\GWlcnXhd4V{KEGtdDDhcoQheC2Da4SgcIV3\Wy|wrDkc5NmNWSncHXu[IVvfGy7 MWSyNlQxPzJ{OB?=
Kasumi-1 M3Xz[mZ2dmO2aX;uJGF{e2G7 Mn;TNk42NzVxMUCg{txO MV2yOEBp NF3LW2RqdmS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSl7LNU8zKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz Ml6yNlI1ODd{Mki=
HL-60 MlO4SpVv[3Srb36gRZN{[Xl? NGjtSFkzNjVxNT:xNEDPxE1? MnOzNlQhcA>? NIfMdmpqdmS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSl7LNU8zKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MoDHNlI1ODd{Mki=
K562 Mn;PSpVv[3Srb36gRZN{[Xl? NVvac4NGOjBizszN MkfJOFghcA>? NXvtS|BNcW6mdXPld{BifXSxcHjh[5nDqA>? NUnHc5BFOjJ2MEeyNlg>
OCUT1 NFnxRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnpUmhMOC5zLUOg{txO M4eyelUh\A>? M4fydYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NWXifIw3OjJyOUCyO|E>
K1 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv3WVgxNjFvMzFOwG0> M3HaW|Uh\A>? NGf2ZXBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NEX3WJEzOjB7MEK3NS=>
OCUT1 M1;TOmZ2dmO2aX;uJGF{e2G7 M2\0[|Mh|ryv MlvsNlQhcA>? MYXjZZV{\XNiYTDkdoFu[XSrYzDpcoNz\WG|ZTDpckBIOi:PIIDoZZNm NW[5ZlJXOjJyOUCyO|E>
CaOV3 MoDRR4VtdCCYaXHibYxqfHliQYPzZZk> NV7WS2xPOS93L{GwJO69VQ>? Mn\2OFghcA>? NYC0XoRW\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyJINwfHKnYYTl[EB4cXSqIIDhZ4xqfGG6ZXy= NV\mdmhHOjF5N{WwOVQ>
SKOV3 NWXhNGRbS3m2b4TvfIlkcXS7IFHzd4F6 M3T3XVUh|ryP MkjuOFghcA>? MlTu[Y5p[W6lZYOgdIFkdGm2YYjlcEBqdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> NGfn[ogzOTd5NUC1OC=>
A2780 NH3meZFEgXSxdH;4bYNqfHliQYPzZZk> M{frNVUh|ryP MknEOFghcA>? MX\lcohidmOnczDwZYNtcXSjeHXsJIlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg NXTYNHVOOjF5N{WwOVQ>
HT-29  MmHGR5l1d3SxeHnjbZR6KEG|c3H5 MUi1JO69VQ>? MnXpOFghcA>? MoXk[Y5p[W6lZYOgdIFkdGm2YYjlcEBqdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> NV;jd4s5OjF5N{WwOVQ>
A498 NEPjUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTDNE01OCEQvF2= MXS3NkBp MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NYrKc|V4OjF4NESwOVA>
CAKI-1 M37TPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOwMVQxKM7:TR?= NWfhT5p[PzJiaB?= MlnITWM2OH5zMDFOwG0> M3LSOFIyPjR2MEWw
769-P MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTX[ZMxNTRyIN88US=> MVS3NkBp MlzVTWM2OH53LUGwJO69VQ>? M2D3eFIyPjR2MEWw
786-0 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm0UFdbOC12MDFOwG0> NWrUT5J3PzJiaB?= NXzwbmtbUUN3MI61JO69VQ>? MlrPNlE3PDRyNUC=
786-O MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvyNFkxNTJyIN88US=> NVHSTFFFPzJiaB?= NWeyb4l7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2PBb|IyPjR2MEWw
CAKI-1 NVLae3ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13PO|AuOjBizszN M{nBXlczKGh? M3j5U4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MXiyNVY1PDB3MB?=
769-P Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGwMVIxKM7:TR?= NHjKfWo4OiCq MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M3PjSlIyPjR2MEWw
A498 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjXW3pTOC1{MDFOwG0> MUC3NkBp NUXTOHR2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M3q0dlIyPjR2MEWw
CWR22RV1 Mkn0R4VtdCCYaXHibYxqfHliQYPzZZk> M3LnOFExKM7:TR?= NYDxOHVQOjRiaB?= MUfpcoNz\WG|ZYOgd4Vve2m2aY\peJkhd2ZiaIXtZY4hS1eUMkLSWlEh[2WubIOgeI8hemGmaXH0bY9v M3fBXlIyPDl4Mkez
CWR22RV1 NX3JSlJRSXCxcITvd4l{KEG|c4PhfS=> MYSxNEDPxE1? MWeyOEBp M4[0W4VvcGGwY3XzJJJi\GmjdHnvckBqdmS3Y3XkJIFxd3C2b4Ppdy=> NVe4[YxROjF2OU[yO|M>
CWR22RV1 NVzBTZNLTnWwY4Tpc44hSXO|YYm= NHiye5k2KM7:TR?= NF;3To8zPCCq MYLy[YR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDBb5Qhe2mpbnnmbYNidnSueR?= MYGyNVQ6PjJ5Mx?=
HepG2  NYfkRW5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyyUY82NzFyL{KwM|QxKM7:TR?= MoHxNlQwPDhxN{KgbC=> NETHS4NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MUeyNFg1OjR{NR?=
Bel-7402 NWm2eoRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUW1M|ExNzJyL{SwJO69VQ>? M4C0flI1NzR6L{eyJIg> MoPGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlXUNlA5PDJ2MkW=
HepG2  NFTnTXBHfW6ldHnvckBCe3OjeR?= NEPWfm82NzFyL{KwJO69VQ>? NH7veXgzPCCq MWjy[ZN2dHS|IHnuJJRp\SCjY3P1cZVt[XSrb36gc4Yh[2WubDDueY1j\XJiaX6geIhmKEd{L12gdIhie2V? NXzXc3d4OjB6NEK0NlU>
Bel-7402 MYnGeY5kfGmxbjDBd5NigQ>? MV[1M|ExNzJyIN88US=> M4Ttc|I1KGh? NUjYWplbemW|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl NX\lfYFqOjB6NEK0NlU>
HepG2  MWnBdI9xfG:|aYOgRZN{e2G7 NIPDUYI2NzFyL{KwJO69VQ>? MljSNlQwPDhiaB?= MX3pcoR2[2W|IHHwc5B1d3OrczDheEB1cGVibH;u[{11cW2nIHX4dI9{fXKn MWSyNFg1OjR{NR?=
Bel-7402 NF7wdG9CeG:ydH;zbZMhSXO|c3H5 MnHnOU8yOC9{MDFOwG0> M2raZ|I1NzR6IHi= M3XmeYlv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW= NY\Id2RJOjB6NEK0NlU>
OAW-42 M3LyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHTNE01OCEQvF2= MnPWO|LDqGh? NXPPNZJUUUN3MI6xNEDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NY\CVHI5OjB2MEWyPVY>
PA-1  M3vqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvTSFJkOC12MDFOwG0> MXe3NuKhcA>? NF7odmFKSzVyfkK1JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MUiyNFQxPTJ7Nh?=
SKOV3  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTKNE01OCEQvF2= M1HydVczyqCq MmL3TWM2OH5|MDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWCyNFQxPTJ7Nh?=
A2780 NX\E[GE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;KNE0zOCEQvF2= NFKxOYc1QC95MjDo NGXJbYxKSzVywrC9xsA{yqEQvH2= MWmyNFQxPTJ7Nh?=
A2780cis  M1rDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPDbYwxNTJyIN88US=> NFHSXFg1QC95MjDo NF3mcY1KSzVywrC9xsA3yqEQvH2= NGfIZnQzODRyNUK5Oi=>
SKW6.4 NWn5VWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nrfFIuOTEEoN88US=> M2\HZ|Q5yqCq NFzIWZdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Ml\UNlAyOzB7NkC=
MAVER MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHJVJkzNTFywrFOwG0> NGPIdFY1QMLiaB?= M3vaRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M3TtbVIxOTNyOU[w
BJAB NY\r[o1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHix[owzNTFywrFOwG0> M2TV[VQ5yqCq NUfBOYsycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEnS[YMzODF|MEm2NC=>
OCI M{fSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfpbmUzNTFywrFOwG0> MYO0POKhcA>? MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MkD6NlAyOzB7NkC=
MOLM MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jkc|IuOTEEoN88US=> M{nGOFQ5yqCq NUixXoJVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFPt[lgzODF|MEm2NC=>
HL-60 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PLU|IuOTEEoN88US=> NG\2Wpg1QMLiaB?= MmTqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MnvENlAyOzB7NkC=
SKW6.4 M1vqdWFxd3C2b4Ppd{BCe3O|YYm= NIe3W5YyOMLizszN MoHUNlQwPDhiaB?= M3LObolv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= NEn3PIozODF|MEm2NC=>
MAVER MmrkRZBweHSxc3nzJGF{e3OjeR?= NFnTdWkyOMLizszN MWqyOE81QCCq NIq0cnpqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 NWnGZ25{OjBzM{C5OlA>
BJAB NV3oZnFCSXCxcITvd4l{KEG|c4PhfS=> NVrYcJNCOTEEoN88US=> NULLWJRkOjRxNEigbC=> NF7sUWpqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 MnPtNlAyOzB7NkC=
OCI M3nPT2Fxd3C2b4Ppd{BCe3O|YYm= M33uVlExyqEQvF2= NETz[FIzPC92ODDo M1vofolv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= MmmwNlAyOzB7NkC=
MOLM MmnRRZBweHSxc3nzJGF{e3OjeR?= NIHtPVUyOMLizszN NYTrZYpVOjRxNEigbC=> NEfaUGxqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 MnfJNlAyOzB7NkC=
HL-60 NUexZmRPSXCxcITvd4l{KEG|c4PhfS=> MYexNOKh|ryP M4HL[FI1NzR6IHi= NGTM[ZRqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 Mmr3NlAyOzB7NkC=

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents individually and in order:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Active, not recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Unknown status Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID